Editas Medicine (EDIT) and Genevant Sciences said Monday they will combine Editas' CRISPR Cas12a genome editing systems with Genevant's LNP technology in the development of in vivo gene editing medicines for two targets in Editas' upregulation strategy.
Genevant granted Editas a nonexclusive license to exploit mRNA-CRISPR Cas12a-LNP products for the targets, with Genevant eligible to receive up to $238 million in upfront and contingent milestone payments, according to the companies.
Price: 3.8100, Change: +0.05, Percent Change: +1.33
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。